(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 9.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Genmab A's revenue in 2023 is $2,421,479,374.On average, 5 Wall Street analysts forecast GMAB's revenue for 2023 to be $156,461,537,044, with the lowest GMAB revenue forecast at $155,045,182,386, and the highest GMAB revenue forecast at $158,465,495,878. On average, 6 Wall Street analysts forecast GMAB's revenue for 2024 to be $178,125,196,199, with the lowest GMAB revenue forecast at $173,795,133,494, and the highest GMAB revenue forecast at $187,636,931,438.
In 2025, GMAB is forecast to generate $212,438,003,131 in revenue, with the lowest revenue forecast at $197,994,330,435 and the highest revenue forecast at $223,701,847,967.